서울대학교, University of Texas MD Anderson Cancer Center

CV(PDF)

이메일
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
펼치기 Authors and Affiliations
Abstract
Metformin has been reported to possess antitumor activity and maintain high cytotoxic T lymphocyte (CTL) immune surveillance. However, the functions and detailed mechanisms of metformin’s role in cancer immunity are not fully understood. Here, we show that metformin increases CTL activity by reducing the stability and membrane localization of programmed death ligand-1 (PD-L1). Furthermore, we discover that AMP-activated protein kinase (AMPK) activated by metformin directly phosphorylates S195 of PD-L1. S195 phosphorylation induces abnormal PD-L1 glycosylation, resulting in its ER accumulation and ER-associated protein degradation (ERAD). Consistently, tumor tissues from metformin-treated breast cancer patients exhibit reduced PD-L1 levels with AMPK activation. Blocking the inhibitory signal of PD-L1 by metformin enhances CTL activity against cancer cells. Our findings identify a new regulatory mechanism of PD-L1 expression through the ERAD pathway and suggest that the metformin-CTLA4 blockade combination has the potential to increase the efficacy of immunotherapy.
 
주소복사
논문정보   
- 형식: Research article
- 게재일: 2018년 08월 (BRIC 등록일 2020-03-30)
- 연구진: 국내+국외 연구진
- 분야: Cancer Biology/Oncology, Cell_Biology, Molecular_Biology
- 피인용횟수: 최근 3년간 60회 이상 인용된 논문
댓글 (0)
웨비나 참석자 모집중...
HOME   |   이용약관   |   개인정보처리방침
© BRIC